Patents by Inventor Stefano Rivella
Stefano Rivella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295658Abstract: Methods and compositions for improved gene therapy are disclosed.Type: ApplicationFiled: November 10, 2021Publication date: September 21, 2023Inventors: Stefano Rivella, Perry Demsko
-
Publication number: 20230287449Abstract: In one aspect of the instant invention, lentiviral vectors are provided, particularly for treating hemoglobinopathies. Composition comprising the lentiviral vector are also encompassed by the instant invention. In accordance with another aspect of the instant invention, methods of inhibiting, treating, and/or preventing a hemoglobinopathy (e.g., sickle cell disease or thalassemia) in a subject are provided. In a particular embodiment, the method comprises administering a viral vector of the instant invention to a subject in need thereof hemoglobinopathy. In a particular embodiment, the subject has sickle cell anemia.Type: ApplicationFiled: April 30, 2019Publication date: September 14, 2023Inventors: Stefano RIVELLA, Laura BREDA, Alisa DONG, Silvia Pires LOURENCO, Amaliris GONZALEZ
-
Patent number: 11674427Abstract: A heating device for an exhaust system of an internal combustion engine and having: a tubular body, where a combustion chamber is obtained on the inside; a fuel injector, which injects fuel into the combustion chamber; at least one inlet opening, which can be connected to a fan so as to receive an air flow, which is directed to the combustion chamber and gets mixed with the fuel; a feeding channel, which receives air from the inlet opening, surrounds an end portion of the fuel injector and ends with a nozzle, which is arranged around an injection point of the fuel injector; and a spark plug, which is mounted through a side wall of the tubular body so as to trigger the combustion of a mixture of air and fuel. The fuel injector is configured to spray at least 80% of the fuel against an inner surface of the feeding channel.Type: GrantFiled: December 16, 2021Date of Patent: June 13, 2023Assignee: MARELLI EUROPE S.P.A.Inventors: Mauro Brignone, Marco La Sana, Emanuele Milani, Stefano Rivella
-
Publication number: 20220389448Abstract: Methods and compositions for producing heme and treating sideroblastic anemia are disclosed.Type: ApplicationFiled: June 29, 2020Publication date: December 8, 2022Inventors: Stefano RIVELLA, Joseph OVED
-
Publication number: 20220202958Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a polynucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a ?T87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.Type: ApplicationFiled: March 15, 2022Publication date: June 30, 2022Inventors: Stefano Rivella, Laura Breda, Alisa Dong, Gerd Blobel, Wulan Deng
-
Publication number: 20220195908Abstract: A heating device for an exhaust system of an internal combustion engine and having: a tubular body, where a combustion chamber is obtained on the inside; a fuel injector, which injects fuel into the combustion chamber; at least one inlet opening, which can be connected to a fan so as to receive an air flow, which is directed to the combustion chamber and gets mixed with the fuel; a feeding channel, which receives air from the inlet opening, surrounds an end portion of the fuel injector and ends with a nozzle, which is arranged around an injection point of the fuel injector; and a spark plug, which is mounted through a side wall of the tubular body so as to trigger the combustion of a mixture of air and fuel. The fuel injector is configured to spray at least 80% of the fuel against an inner surface of the feeding channel.Type: ApplicationFiled: December 16, 2021Publication date: June 23, 2022Applicant: MARELLI EUROPE S.P.A.Inventors: Mauro Brignone, Marco La Sana, Emanuele Milani, Stefano Rivella
-
Patent number: 11311632Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a poly-nucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a PT87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.Type: GrantFiled: January 21, 2016Date of Patent: April 26, 2022Assignees: CORNELL UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Stefano Rivella, Laura Breda, Alisa Dong, Gerd Blobel, Wulan Deng
-
Publication number: 20220090567Abstract: A heating device for an exhaust system of an internal combustion engine; the heating device has: a first tubular body wherein a combustion chamber is obtained; a fuel injector to inject fuel into the combustion chamber; an inlet opening, which is obtained through the first tubular body and can be connected to a fan to receive an air flow, which is directed into the combustion chamber; a hot air outlet opening to let hot air out of the combustion chamber; an outlet duct, which originates from the outlet opening; a spark plug which is mounted through a side wall of the first tubular body to trigger the combustion of a mixture of air and fuel; and a labyrinth, which surrounds a side wall of the tubular body, starts from the inlet opening, ends in the combustion chamber, and the air must necessarily flow out of the inlet opening until reaching the combustion chamber.Type: ApplicationFiled: September 15, 2021Publication date: March 24, 2022Applicant: MARELLI EUROPE S.p.A.Inventors: Mauro Brignone, Emanuele Milani, Stefano Rivella, Marco La Sana
-
Publication number: 20210252106Abstract: The present invention provides methods, agents, compounds, and compositions useful for administering to subjects having or at risk of having anemias. In certain embodiments, methods herein comprise administering two agents to a subject, which are useful for the treatment of an anemia.Type: ApplicationFiled: April 30, 2019Publication date: August 19, 2021Inventors: Stefano RIVELLA, Carla CASU
-
Publication number: 20210222200Abstract: Methods and compositions for producing hemoglobin and treating alpha-thalassemia are disclosed.Type: ApplicationFiled: September 16, 2019Publication date: July 22, 2021Inventors: Stefano Rivella, Maxwell Chappell
-
Publication number: 20180008725Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a polynucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a PT87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.Type: ApplicationFiled: January 21, 2016Publication date: January 11, 2018Inventors: Stefano RIVELLA, Laura BREDA, Alisa DONG, Gerd BLOBEL, Wulan DENG
-
Patent number: 8058061Abstract: Recombinant lentiviral vectors having a region encoding a functional ?-globin gene; and large portions of the ?-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of ?-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including ?-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug.Type: GrantFiled: April 30, 2009Date of Patent: November 15, 2011Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Michel Sadelain, Stefano Rivella, Chad May, Joseph Bertino
-
Publication number: 20090274671Abstract: Recombinant lentiviral vectors having a region encoding a functional ?-globin gene; and large portions of the ?-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of ?-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including ?-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug.Type: ApplicationFiled: April 30, 2009Publication date: November 5, 2009Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Michel Sadelain, Stefano Rivella, Chad May, Joseph Bertino
-
Patent number: 7541179Abstract: Recombinant lentiviral vectors having a region encoding a functional ?-globin gene; and large portions of the ?-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of ?-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including ?-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than un-transformed cells allows selection by treatment of the cells with the corresponding drug.Type: GrantFiled: July 1, 2002Date of Patent: June 2, 2009Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Michel Sadelain, Stefano Rivella, Chad May, Joseph Bertino
-
Publication number: 20030022303Abstract: Recombinant lentiviral vectors having a region encoding a functional &bgr;-globin gene; and large portions of the &bgr;-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of &bgr;-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including &bgr;-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than un-transformed cells allows selection by treatment of the cells with the corresponding drug.Type: ApplicationFiled: July 1, 2002Publication date: January 30, 2003Inventors: Michel Sadelain, Stefano Rivella, Chad May, Joseph Bertino